Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India Orders Post-Marketing Data For Pfizer’s Champix

This article was originally published in PharmAsia News

Executive Summary

India's drug regulator has instructed U.S. drug maker Pfizer's Indian subsidiary to submit post-marketing data on the impact of its Champix (varenicline) drug to help smokers quit. Although Indian physicians have not reported seeing problems with use of the psychotropic drug, Pfizer was instructed to complete its post-marketing study by May of next year, followed by regular updates. A Pfizer Ltd. official said the study already is underway with 300 patients at 21 sites. India's post-marketing surveillance regulations usually are followed only if the government specifically orders them. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts